We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

53 hedge funds and large institutions have $129M invested in Orchestra BioMed in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

10% more funds holding

Funds holding: 48 → 53 (+5)

7% more capital invested

Capital invested by funds: $121M → $129M (+$8.35M)

3.1% more ownership

Funds ownership: 59.66% → 62.75% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
53
Holders Change
+5
Holders Change %
+10.42%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
11
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$5.19M
2
WAM
Weiss Asset Management
Massachusetts
+$1.78M
3
KKRC
Kohlberg Kravis Roberts & Co
New York
+$1.67M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$1.48M
5
HI
HBK Investments
Texas
+$606K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.87M
2
IC
Ikarian Capital
Texas
-$1.95M
3
AC
Athanor Capital
New York
-$215K
4
BFM
Boothbay Fund Management
New York
-$169K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$89.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
26
Bank of Montreal
Ontario, Canada
$1.48M +$1.48M +150,000 New
Millennium Management
27
Millennium Management
New York
$1.21M +$226K +22,940 +24%
Wellington Management Group
28
Wellington Management Group
Massachusetts
$1.13M -$3.87M -392,383 -78%
WRBC
29
W.R. Berkley Corp
Connecticut
$1.1M – – –
PVI
30
Pura Vida Investments
New York
$1.04M -$27.4K -2,776 -3%
Marshall Wace
31
Marshall Wace
United Kingdom
$803K +$3.94K +400 +0.5%
PMAM
32
Picton Mahoney Asset Management
Ontario, Canada
$792K – – –
HI
33
HBK Investments
Texas
$620K +$606K +61,533 New
DFCM
34
Dark Forest Capital Management
Puerto Rico
$548K +$536K +54,395 New
SCM
35
Shaolin Capital Management
Florida
$504K – – –
TD Asset Management
36
TD Asset Management
Ontario, Canada
$463K – – –
MF
37
Magnetar Financial
Illinois
$413K +$6.61K +671 +2%
Alyeska Investment Group
38
Alyeska Investment Group
Illinois
$252K – – –
Nomura Holdings
39
Nomura Holdings
Japan
$204K +$49.3K +5,000 +32%
WAM
40
Wolverine Asset Management
Illinois
$198K -$19.7K -2,000 -9%
SC
41
Sagefield Capital
Texas
$184K +$180K +18,300 New
HF
42
HRT Financial
New York
$158K +$156K +15,809 New
Geode Capital Management
43
Geode Capital Management
Massachusetts
$124K +$20K +2,033 +20%
BCM
44
Basso Capital Management
Connecticut
$106K – – –
6CM
45
683 Capital Management
New York
$101K – – –
ACM
46
Altium Capital Management
New York
$101K – – –
RCM
47
Rivernorth Capital Management
Florida
$101K – – –
CM
48
Cohanzick Management
New York
$101K +$98.5K +10,000 New
PCM
49
Pinz Capital Management
New York
$65K +$63.1K +6,400 New
AA
50
Ancora Advisors
Ohio
$54K – – –
1
2
3

OBIO Hedge Fund Activity: Q4 2021 in Review

53 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q4 2021, worth a combined $129M — up 6.9% from $121M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new OBIO positions and 4 closed out — a net gain of 5 holders — while 11 added to existing stakes and 5 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $5.19M. The largest seller was Wellington Management Group, cutting an estimated $3.87M.

  • 53 institutional investors held Orchestra BioMed (OBIO) as of Q4 2021, up from 48 in Q3 2021.
  • Funds reported $129M of Orchestra BioMed stock for Q4 2021, up 6.9% quarter-over-quarter.
  • 9 funds opened new Orchestra BioMed positions in Q4 2021 and 4 closed out, a net change of +5 holders.
  • The largest Orchestra BioMed buyer in Q4 2021 was D.E. Shaw & Co, an estimated $5.19M added.
  • The largest Orchestra BioMed seller in Q4 2021 was Wellington Management Group, an estimated $3.87M sold.

Based on aggregated 13F filings for Q4 2021.